Association of plasminogen activator inhibitor-1 and cardiovascular events development in patients with prediabetes
Laryushina Y. Parakhina V. Turgunova L. Sheryazdanova D. Dosmagambetova R. Turmukhambetova A. Ponamareva O. Orbetzova M.
26 December 2021Scientific Foundation SPIROSKI
Open Access Macedonian Journal of Medical Sciences
2021#9726 - 733 pp.
BACKGROUND: Plasminogen activator inhibitor-1 (PAI-1) is a marker of endothelial dysfunction (ED) and a predictor of both the development of type 2 diabetes mellitus, and a cardiovascular event (CVE). Its role in the CVE development was sufficiently studied in patients without carbohydrate metabolism disorders, and understudied in patients with prediabetes. AIM: The research interest is the study of PAI-1 in patients with prediabetes and its effect on the CVE development. MATERIALS AND METHODS: The case–control study of 168 patients aged from 18 to 65 was carried out among the local population from January to December 2019. After clinical examination, patients were divided into three groups: Group 1 (n = 55)– patients with prediabetes and with CVE; and Group 2 (n = 93) – patients with prediabetes and without CVE; the control group n = 20. RESULTS: Differences in PAI-1 level were found in groups 1 (Me = 30718.6 pg/ml) and 2 (Me = 24692.0 pg/ml; p ≤ 0.001), even greater differences were found in both groups compared to the control one (p ≤ 0.001). The correlation analysis has found in both group influences such IR indicators as fasting glucose, IR-HOMA index, glucagon, and C-peptide to elevation of PAI-1. These findings indicate that with an elevation of the PAI-1 level, the concentration of fasting glucose, glucagon, C-peptide, and scores of IR-HOMA index increase in both groups. The Binary regression analysis has demonstrated that an elevation of the PAI-1 biomarker increases the likelihood of CVE by 3.3 fold in patients with prediabetes (p ≤ 0.01). In addition to, a model has been derived for assessing the risk of CVEs in patients with prediabetes. CONCLUSIONS: Elevation of PAI-1 concentration is associated with insulin resistance which leads to ED, and further development risk of CVE in patients with prediabetes.
Cardiovascular event , Endothelial dysfunction , Plasminogen activator inhibitor-1 , Prediabetes
Text of the article Перейти на текст статьи
Department of Internal Medicine, Karaganda Medical University, Karaganda, Kazakhstan
Department of Strategic Development and Science, Karaganda Medical University, Karaganda, Kazakhstan
Department of Biochemistry, Karaganda Medical University, Karaganda, Kazakhstan
Department of Endocrinology, Medical University of Plovdiv, Plovdiv, Bulgaria
Department of Internal Medicine
Department of Strategic Development and Science
Department of Biochemistry
Department of Endocrinology
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026